Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY – Get Free Report) was the recipient of a significant decline in short interest during the month of June. As of June 30th, there was short interest totaling 65,513 shares, a decline of 54.0% from the June 15th total of 142,536 shares. Based on an average trading volume of 1,245,678 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the shares of the company are sold short.
Coloplast A/S Stock Up 1.3%
CLPBY opened at $6.20 on Tuesday. Coloplast A/S has a 52 week low of $5.64 and a 52 week high of $10.03. The business has a 50 day moving average price of $6.08 and a two-hundred day moving average price of $7.05. The company has a quick ratio of 1.09, a current ratio of 1.75 and a debt-to-equity ratio of 1.66. The company has a market cap of $13.97 billion, a PE ratio of 44.29, a P/E/G ratio of 1.94 and a beta of 0.22.
Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.01. The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.11 billion. Coloplast A/S had a return on equity of 33.15% and a net margin of 7.46%. As a group, research analysts anticipate that Coloplast A/S will post 0.38 EPS for the current year.
Wall Street Analyst Weigh In
Read Our Latest Report on Coloplast A/S
Coloplast A/S Company Profile
Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.
In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.
Featured Stories
- Five stocks we like better than Coloplast A/S
- CEOs Sell Millions Worth of These 3 Big Name Stocks—What It Means for Investors
- Fission for Profits: Unlocking America’s Uranium Vault
- The SK Hynix IPO and 2027’s AI Memory Squeeze
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.
